https://www.selleckchem.com/pr....oducts/NVP-AUY922.ht
5% cPR - clinical pregnancy rate), 30live births (35.3% LBR - live birth rate), 3(3.5%) early moderate ovarian hyperstimulation syndroms (OHSS) and no hospitalization due to the treatment. Individualized ovarian stimulation optimizes ovarian response, maintains treatment efficacy and improves safety by reducing OHSS incidence. The results of the Czech population study are fully comparable with the international, randomized, assessor-blinded trial ESTHER-1. Individualized ovarian stimulation optimizes ovarian response, maintains treat
Aimer
Commentaire
Partagez
